Citation

Iwamoto K, Fujishiro H, Ozaki N. Psychiatry Clin. Neurosci. 2016; 71(1): 74-75.

Affiliation

Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Copyright

(Copyright © 2016, John Wiley and Sons)

DOI

10.1111/pcn.12479

PMID

27862744

Abstract

Although late-life depression is major concern, half of patients fail to respond to first-line pharmacotherapy. Secondary strategies are required and recent study showed that aripiprazole augmentation is useful treatment. This report shows that aripiprazole augmentation can obscure Lewy body disease in late-life depression. Aripiprazole augmentation initially ameliorates depressive symptoms of Lewy body disease without triggering extrapyramidal dysfunction and eventually becomes less effective and evokes extrapyramidal dysfunction as the disease progresses. Progression of Lewy body disease may affect both efficacy and tolerability of aripiprazole augmentation. Clinician should reconsider diagnosis of depressive patients in late-life who are responsive to aripiprazole augmentation.

This article is protected by copyright. All rights reserved.

Language: en